Rolipram and pentoxifylline combination ameliorates experimental diabetic neuropathy through inhibition of oxidative stress and inflammatory pathways in the dorsal root ganglion neurons.

Abstract

Diabetic neuropathy (DN) is the most challenging microvascular complication of diabetes and there is no suitable treatment for it, so the development of new agents to relieve DN is urgently needed. Since oxidative stress and inflammation play an essential role in the development of DN, clearance of these factors are good strategies for the treatment of this disease. According to key role of cyclic adenosine monophosphate (cAMP) in the regulation of oxidative stress and inflammatory pathways, it seems that phosphodiesterase inhibitors (PDEIs) can be as novel drug targets for improving DN through enhancement of cAMP level. The aim of this study was to evaluate the effects of rolipram, a selective PDE4 inhibitor, and pentoxifylline, a general PDE inhibitor on experimental model of DN and also to determine the possible mechanisms involved in the effectiveness of these agents. We investigated the effects of rolipram (1 mg/kg) and pentoxifylline (100 mg/kg) and also combination of rolipram (0.5 mg/kg) and pentoxifylline (50 mg/kg), orally for five weeks in rats that became diabetic by STZ (55 mg/kg, i.p.). After treatments, motor function was evaluated by open-field test, then rats were anesthetized and dorsal root ganglion (DRG) neurons isolated. Next, oxidative stress biomarkers and inflammatory factors were assessed by biochemical and ELISA methods, and RT-PCR analysis in DRG neurons. Rolipram and/or pentoxifylline treatment significantly attenuated DN - induced motor function deficiency by modulating distance moved and velocity. Rolipram and/or pentoxifylline treatment dramatically increased the cAMP level, as well as suppressed DN - induced oxidative stress which was associated with decrease in LPO and ROS and increase in TAC, total thiol, CAT and SOD in DRG neurons. On the other hand, the level of inflammatory factors (TNF-α, NF-kB and COX2) significantly decreased following rolipram and/or pentoxifylline administration. The maximum effectiveness was with rolipram and/or pentoxifylline combination on mentioned factors. These findings provide novel experimental evidence for further clinical investigations on rolipram and pentoxifylline combination for the treatment of DN.

• Authors: Mona Dastgheib, Seyed Vahid Shetab-Boushehri, Maryam Baeeri, Mahdi Gholami, Mohammad Yahya Karimi, Asieh Hosseini
• Journal: Metabolic brain disease (Metab Brain Dis) Vol. 37 Issue 7 Pg. 2615-2627 (10 2022) ISSN: 1573-7365 [Electronic] United States
• PMID: 35922732 (Publication Type: Journal Article)
• Copyright: © 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Chemical References

• Rolipram
• Pentoxifylline
• Phosphodiesterase 4 Inhibitors
• Tumor Necrosis Factor-alpha
• Reactive Oxygen Species
• NF-kappa B
• Cyclooxygenase 2
• Biomarkers
• Sulfhydryl Compounds
• Adenosine Monophosphate
• Superoxide Dismutase

Topics

• Animals
• Rats
• Rolipram (pharmacology, therapeutic use)
• Pentoxifylline (pharmacology, therapeutic use)
• Diabetic Neuropathies (drug therapy)
• Ganglia, Spinal (metabolism)
• Phosphodiesterase 4 Inhibitors (pharmacology)
• Tumor Necrosis Factor-alpha (metabolism)
• Reactive Oxygen Species
• NF-kappa B (metabolism)
• Cyclooxygenase 2 (metabolism)
• Oxidative Stress
• Neurons (metabolism)
• Biomarkers (metabolism)
• Sulfhydryl Compounds
• Adenosine Monophosphate (metabolism)
• Superoxide Dismutase (metabolism)